GlassScriptPhysician profile
Leslie Spires
NPI 1295490910
$2,565.36
in general payments reported to CMS, 2019-2025
28 companies · $741 in 2025
The $741 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.38 · 2022: $587 · 2023: $611 · 2024: $563 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,914.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.39 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $402.88 | 2022-2025 | |
| Astellas Pharma US INC | $199.15 | 2022-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $161.77 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.39 | 2022-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $144.87 | 2021-2022 | |
| Novo Nordisk INC | $107.90 | 2022-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $91.75 | 2022-2023 | Verquvo |
| Nestle Healthcare Nutrition INC. | $82.56 | 2022-2023 | |
| Harmony Biosciences LLC | $81.14 | 2024-2025 | |
| Glaxosmithkline, LLC. | $73.41 | 2022-2025 | Trelegy Ellipta |
| Amgen INC. | $72.84 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $60.63 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $59.93 | 2021-2025 | Trintellix |
| Smith+Nephew, INC. | $51.35 | 2022-2024 | Collagenase Santyl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $50.48 | 2023-2025 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $45.92 | 2024-2025 | Nuzyra |
| Otsuka America Pharmaceutical, INC. | $35.57 | 2023-2024 | Rexulti, Nuedexta |
| Eisai INC. | $34.23 | 2022-2023 | |
| Lilly USA, LLC | $22.80 | 2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $21.41 | 2024 | Farxiga |
| Vertex Pharmaceuticals Incorporated | $19.88 | 2025 | |
| Global Blood Therapeutics, INC. | $18.33 | 2021 | |
| Ardelyx, INC. | $17.38 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.23 | 2023 | Jardiance |
| Hikma Pharmaceuticals USA | $16.69 | 2022 | |
| Aimmune Therapeutics, INC. | $14.12 | 2025 | Vowst |
| Athena Bioscience, LLC | $6.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Spires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.